CancerDrs

Sarcoma clinical trials in Georgia

27 actively recruiting sarcoma trials at 11 sites across Georgia.

Data from ClinicalTrials.gov · last refreshed

Payments from drug makers to the doctors running these trials

For 2 of the trials on this page, the pharmaceutical company funding the trial also disclosed payments to the physicians leading it — public data from the federal CMS Open Payments database. Paying clinical-trial investigators for site work is expected and necessary for industry-funded trials; the scale and source are simply useful context when you're deciding whether to enroll.

Phase 3 Recruiting NIH

Measuring if Immunotherapy Plus Chemotherapy is Better Than Chemotherapy Alone for Patients With Aggressive Poorly Differentiated Sarcomas

This phase III trial compares the effect of immunotherapy (pembrolizumab) plus chemotherapy (doxorubicin) to chemotherapy (doxorubicin) alone in treating patients with dedifferentiated liposarcoma (DDLPS), undifferentiated pleomorphic sarc…

Sponsor: National Cancer Institute (NCI)
NCT ID: NCT06422806
Sites in Georgia:
  • Emory University Hospital Midtown — Atlanta, Georgia
View on ClinicalTrials.gov →
Phase 3 Recruiting Network

Thoracotomy Versus Thoracoscopic Management of Pulmonary Metastases in Patients With Osteosarcoma

This phase III trial compares the effect of open thoracic surgery (thoracotomy) to thoracoscopic surgery (video-assisted thoracoscopic surgery or VATS) in treating patients with osteosarcoma that has spread to the lung (pulmonary metastase…

Sponsor: Children's Oncology Group
NCT ID: NCT05235165
Sites in Georgia:
  • Children's Healthcare of Atlanta - Arthur M Blank Hospital — Atlanta, Georgia
View on ClinicalTrials.gov →
Phase 2, Phase 3 Recruiting NIH

A Study to Test the Addition of the Drug Cabozantinib to Chemotherapy in Patients With Newly Diagnosed Osteosarcoma

This phase II/III trial tests the safety, side effects, and best dose of the drug cabozantinib in combination with standard chemotherapy, and to compare the effect of adding cabozantinib to standard chemotherapy alone in treating patients …

Sponsor: National Cancer Institute (NCI)
NCT ID: NCT05691478
Sites in Georgia:
  • Children's Healthcare of Atlanta - Arthur M Blank Hospital — Atlanta, Georgia
  • Augusta University Medical Center — Augusta, Georgia
  • Memorial Health University Medical Center — Savannah, Georgia
View on ClinicalTrials.gov →
Phase 3 Recruiting Network

Chemotherapy for the Treatment of Patients With Newly Diagnosed Very Low-Risk and Low Risk Fusion Negative Rhabdomyosarcoma

Rhabdomyosarcoma is a type of cancer that occurs in the soft tissues in the body. This phase III trial aims to maintain excellent outcomes in patients with very low risk rhabdomyosarcoma (VLR-RMS) while decreasing the burden of therapy usi…

Sponsor: Children's Oncology Group
NCT ID: NCT05304585
Sites in Georgia:
  • Children's Healthcare of Atlanta - Arthur M Blank Hospital — Atlanta, Georgia
  • Atrium Health Navicent — Macon, Georgia
  • Memorial Health University Medical Center — Savannah, Georgia
View on ClinicalTrials.gov →
Phase 3 Recruiting Network

Surgery With or Without Neoadjuvant Chemotherapy in High Risk RetroPeritoneal Sarcoma

This is a multicenter, randomized, open label phase lll trial to assess whether preoperative chemotherapy, as an adjunct to curative-intent surgery, improves the prognosis of high risk DDLPS (dedifferentiated Liposarcoma) and LMS (Leiomyos…

Sponsor: European Organisation for Research and Treatment of Cancer - EORTC
NCT ID: NCT04031677
Sites in Georgia:
  • Emory University Hospital Midtown — Atlanta, Georgia
View on ClinicalTrials.gov →
Phase 3 Recruiting Academic/Other

Impact of Sentinel Lymph Node Mapping on Patient Reported Lower Extremity Limb Dysfunction in Stage I Endometrial Cancer

This phase III trial compares the effect of sentinel lymph node mapping to standard lymph node dissection in reducing the risk of swelling in the legs (lymphedema) in patients undergoing a hysterectomy for stage I endometrial cancer. Stand…

Sponsor: NRG Oncology
NCT ID: NCT05646316
Sites in Georgia:
  • Augusta University Medical Center — Augusta, Georgia
View on ClinicalTrials.gov →
Phase 1, Phase 2 Recruiting Industry

A Study of Repotrectinib (TPX-0005) in Patients With Advanced Solid Tumors Harboring ALK, ROS1, or NTRK1-3 Rearrangements

Phase 1 dose escalation will determine the first cycle dose-limiting toxicities (DLTs), the maximum tolerated dose (MTD), the biologically effective dose and recommended Phase 2 dose (RP2D) of repotrectinib given to adult subjects with adv…

Sponsor: Turning Point Therapeutics, Inc.
NCT ID: NCT03093116
Sites in Georgia:
  • University Cancer and Blood Center — Athens, Georgia
  • Local Institution - 2134 — Columbus, Georgia
View on ClinicalTrials.gov →
Phase 2 Recruiting Academic/Other

I-SPY TRIAL: Neoadjuvant and Personalized Adaptive Novel Agents to Treat Breast Cancer

The purpose of this study is to further advance the ability to practice personalized medicine by learning which new drug agents are most effective with which types of breast cancer tumors and by learning more about which early indicators o…

Sponsor: QuantumLeap Healthcare Collaborative
NCT ID: NCT01042379
Sites in Georgia:
  • Winship Cancer Institute of Emory University — Atlanta, Georgia
View on ClinicalTrials.gov →
Phase 1, Phase 2 Recruiting Network

Tegavivint for the Treatment of Recurrent or Refractory Solid Tumors, Including Lymphomas and Desmoid Tumors

This phase I/II trial evaluates the highest safe dose, side effects, and possible benefits of tegavivint in treating patients with solid tumors that has come back (recurrent) or does not respond to treatment (refractory). Tegavivint interf…

Sponsor: Children's Oncology Group
NCT ID: NCT04851119
Sites in Georgia:
  • Children's Healthcare of Atlanta - Arthur M Blank Hospital — Atlanta, Georgia
View on ClinicalTrials.gov →
Phase 1, Phase 2 Recruiting Industry

A Study of Repotrectinib in Pediatric and Young Adult Subjects Harboring ALK, ROS1, OR NTRK1-3 Alterations

Phase 1 will evaluate the safety and tolerability at different dose levels of repotrectinib in pediatric and young adult subjects with advanced or metastatic malignancies harboring anaplastic lymphoma kinase (ALK), receptor tyrosine kinase…

Sponsor: Turning Point Therapeutics, Inc.
NCT ID: NCT04094610
Sites in Georgia:
  • Children's Healthcare of Atlanta - Egleston Hospital — Atlanta, Georgia
View on ClinicalTrials.gov →
Phase 2 Recruiting Academic/Other

A Study of Selinexor in People With Wilms Tumors and Other Solid Tumors

The purpose of this study is to find out whether selinexor is an effective treatment for people who have a relapsed/refractory Wilms tumor, rhabdoid tumor, MPNST, BCOR-driven sarcoma, or another solid tumor that makes a higher than normal …

Sponsor: Memorial Sloan Kettering Cancer Center
NCT ID: NCT05985161
Sites in Georgia:
  • Children's Healthcare of Atlanta (Data Collection and Specimen Analysis) — Atlanta, Georgia
View on ClinicalTrials.gov →
Phase 1, Phase 2 Recruiting Industry

Study of Lurbinectedin Monotherapy in Pediatric and Young Adult Participants With Relapsed/Refractory Ewing Sarcoma

This study is conducted in two phases. The phase 1 portion of the study evaluates the safety, tolerability, pharmacokinetics (PK), recommended phase 2 dose (RP2D), and effectiveness of lurbinectedin monotherapy in pediatric participants wi…

Sponsor: Jazz Pharmaceuticals
NCT ID: NCT05734066
Sites in Georgia:
  • Children's Healthcare of Atlanta at Arthur M. Blank Hospital — Atlanta, Georgia
View on ClinicalTrials.gov →
Phase 1, Phase 2 Recruiting Academic/Other

Study of Onivyde With Talazoparib or Temozolomide in Children With Recurrent Solid Tumors and Ewing Sarcoma

The phase I portion of this study is designed for children or adolescents and young adults (AYA) with a diagnosis of a solid tumor that has recurred (come back after treatment) or is refractory (never completely went away). The trial will …

Sponsor: St. Jude Children's Research Hospital
NCT ID: NCT04901702
Sites in Georgia:
  • Children's Healthcare of Atlanta/Emory University School of Medicine — Atlanta, Georgia
View on ClinicalTrials.gov →
Phase 1 Recruiting Industry

A Study to Investigate the Safety and Tolerability of Ziftomenib in Combination With Venetoclax/Azacitidine, Venetoclax, 7+3, or 7+3+Quizartinib in Patients With AML

Ziftomenib is an investigational drug in development for the treatment of patients with acute myeloid leukemia (AML) with certain genetic alterations. This protocol has 3 separate arms that will investigate the benefits and risks of adding…

Sponsor: Kura Oncology, Inc.
NCT ID: NCT05735184
Sites in Georgia:
  • Emory Healthcare - The Emory Clinic — Atlanta, Georgia
  • Georgia Cancer Center at Augusta University — Augusta, Georgia
View on ClinicalTrials.gov →
Phase 1 Recruiting Industry

SynKIR-310 for Relapsed/Refractory B-NHL

This first-in-human (FIH) trial is designed to assess the safety, feasibility and preliminary efficacy of a single intravenous (IV) dose of SynKIR-310 administered to participants with relapsed/refractory B-NHL.

Sponsor: Verismo Therapeutics
NCT ID: NCT06544265
Sites in Georgia:
  • Winship Cancer Institute of Emory University — Atlanta, Georgia
View on ClinicalTrials.gov →
Phase 1 Recruiting Academic/Other

Losartan + Sunitinib in Treatment of Osteosarcoma

This study is a Phase 1/1b clinical trial that aims to determine the Maximally Tolerated Dose of Losartan and Sunitinib Combination Therapy. Patients will first be accrued to the Dose Escalation phase of the study, using a 3+3 design. Medi…

Sponsor: University of Colorado, Denver
NCT ID: NCT03900793
Sites in Georgia:
  • Children's Hospital of Atlanta — Atlanta, Georgia
View on ClinicalTrials.gov →
Phase 1 Recruiting Academic/Other

Study of CAR T-Cells Targeting the GD2 With IL-15+iCaspase9 for Relapsed/Refractory Neuroblastoma or Relapsed/Refractory Osteosarcoma

The body has different ways of fighting infections and disease. No single way seems perfect for fighting cancer. This research study combines two different ways of fighting disease: antibodies and T cells. Antibodies are molecules that fig…

Sponsor: UNC Lineberger Comprehensive Cancer Center
NCT ID: NCT03721068
Sites in Georgia:
  • Emory - Winship Cancer Institute — Atlanta, Georgia
View on ClinicalTrials.gov →
Phase 1 Recruiting Academic/Other

Allogeneic Expanded Gamma Delta T Cells With GD2 Chemoimmunotherapy in Relapsed /Refractory Neuroblastoma or Refractory/ Relapsed Osteosarcoma

The goal of this clinical trial is to determine the maximum tolerated dose (MTD) and recommended Phase II dose (RP2D) of allogeneic expanded γδ T cells when delivered with Dinutuximab, temozolomide, irinotecan, and zoledronate in children …

Sponsor: Emory University
NCT ID: NCT05400603
Sites in Georgia:
  • Children's Healthcare of Atlanta — Atlanta, Georgia
View on ClinicalTrials.gov →
Phase 1 Recruiting Academic/Other

Tegavivint With Gemcitabine in Patients With Relapsed or Refractory Osteosarcoma

The goal of this clinical trial is to define the maximum tolerated dose (MTD) and/or Recommended phase 2 dose (RP2D) of Tegavivint in combination with Gemcitabine in patients with relapsed or refractory osteosarcoma (OS). The study will al…

Sponsor: Emory University
NCT ID: NCT07144254
Sites in Georgia:
  • Arthur M. Blank Children's Healthcare of Atlanta — Atlanta, Georgia
View on ClinicalTrials.gov →
Phase 1 Recruiting Academic/Other

Atezolizumab in Combination With Stereotactic Body Radiation Therapy (SBRT) and Surgery for Relapsed Osteosarcoma

This study aims to determine the safety and tolerability of combined Atezolizumab, stereotactic body radiation therapy (SBRT), and surgical resection of pulmonary metastases in patients with pulmonary recurrence of osteosarcoma

Sponsor: Emory University
NCT ID: NCT06492954
Sites in Georgia:
  • Chilldren's Healthcare of Atlanta — Atlanta, Georgia
View on ClinicalTrials.gov →
Recruiting Academic/Other

Collecting Blood Samples From Patients With and Without Cancer to Evaluate Tests for Early Cancer Detection

This study collects blood and tissue samples from patients with cancer and without cancer to evaluate tests for early cancer detection. Collecting and storing samples of blood and tissue from patients with and without cancer to study in th…

Sponsor: Alliance for Clinical Trials in Oncology
NCT ID: NCT05334069
Sites in Georgia:
  • Northeast Georgia Medical Center Braselton — Braselton, Georgia
  • Atlanta VA Medical Center — Decatur, Georgia
  • Northeast Georgia Medical Center-Gainesville — Gainesville, Georgia
  • The Longstreet Clinic - Gainesville — Gainesville, Georgia
  • Low Country Cancer Care — Savannah, Georgia
View on ClinicalTrials.gov →
Recruiting Network

Effects of Dexrazoxane Hydrochloride on Biomarkers Associated With Cardiomyopathy and Heart Failure After Cancer Treatment

This clinical trial studies the effects of dexrazoxane hydrochloride on biomarkers associated with cardiomyopathy and heart failure after cancer treatment. Studying samples of blood in the laboratory from patients receiving dexrazoxane hyd…

Sponsor: Children's Oncology Group
NCT ID: NCT01790152
Sites in Georgia:
  • Children's Healthcare of Atlanta - Egleston — Atlanta, Georgia
View on ClinicalTrials.gov →
Recruiting Industry

cfDNA Assay Prospective Observational Validation for Early Cancer Detection and Minimal Residual Disease

This is an observational case-control study to train and validate a genome-wide methylome enrichment platform to detect multiple cancer types and to differentiate amongst cancer types. The cancers included in this study are brain, breast, …

Sponsor: Adela, Inc
NCT ID: NCT05366881
Sites in Georgia:
  • North Georgia Health System — Gainesville, Georgia
View on ClinicalTrials.gov →

Showing 25 of 27 trials with sites in Georgia. See all sarcoma trials →

Medical disclaimer: This page aggregates public ClinicalTrials.gov data. It is not medical advice. Always confirm eligibility and enrollment details with the trial site or your oncologist.

Source: ClinicalTrials.gov API v2 · Last checked: 2026-05-25